维亚生物(01873)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01873 维亚生物

午间休市 09-08 12:05:00

1.345

+0.020

+1.51%

最高1.345	最低1.310	成交量101.05万
今开1.325	昨收1.325	日振幅2.64%
总市值28.16亿	流通市值28.16亿	总股本20.94亿
成交额133.75万	换手率0.05%	流通股本20.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01873","market":"HK","secType":"STK","nameCN":"维亚生物","latestPrice":1.345,"timestamp":1788840300003,"preClose":1.325,"halted":0,"volume":1010500,"delay":0,"changeRate":0.015094339622641523,"floatShares":2094000000,"shares":2094000000,"eps":0.09,"marketStatus":"午间休市","change":0.02,"latestTime":"09-08 12:05:00","open":1.325,"high":1.345,"low":1.31,"amount":1337545,"amplitude":0.026415,"askPrice":1.345,"askSize":14000,"bidPrice":1.335,"bidSize":51000,"shortable":3,"etf":0,"ttmEps":0.098,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788843600000},"marketStatusCode":3,"adr":0,"listingDate":1557331200000,"exchange":"SEHK","adjPreClose":1.325,"openAndCloseTimeList":[[1788831000000,1788840000000],[1788843600000,1788854400000]],"volumeRatio":1.972582,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01873","defaultTab":"news","newsList":[{"id":"1143506639","title":"维亚生物2026年8月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1143506639","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143506639?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:13","pubTimestamp":1788513214,"startTime":"0","endTime":"0","summary":"维亚生物科技控股集团于2026年9月4日发布截至2026年8月31日的股份变动月报表。报告期内，公司法定/注册股本總额保持在4,000,000,000股普通股，面值为每股0.000025美元，总注册股本维持在100,000美元。期权与激励计划方面，公告显示公司已有首发前股份奖励计划与首次公开发售后购股权计划。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662227507","title":"港股异动 | 维亚生物(01873.HK)一度跌超10% 上半年经调整净利润同比跌三成 CRO业务收入有所下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662227507","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662227507?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:38","pubTimestamp":1787801916,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01873","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154186272","title":"维亚生物发布2026年中期业绩：AI引领药物研发新范式，CDMO商业化生产加速营收增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1154186272","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154186272?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:58","pubTimestamp":1787756293,"startTime":"0","endTime":"0","summary":"维亚生物公布了其2026年中期业绩报告，揭示了公司在人工智能驱动下的药物研发领域所开创的全新格局。与此同时，CDMO业务的商业化制造能力正成为推动营收攀升的关键引擎。报告显示，AI技术的深度应用正在重塑药物研发的传统路径，为行业带来一场静默而深刻的变革。在另一条战线上，CDMO板块的商业化生产呈现出强劲的扩张势头。展望下半年，随着AI模型的进一步迭代以及商业化项目的陆续交付，公司或将在既有轨道上驶向更广阔的蓝海。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","01873","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154969936","title":"维亚生物(01873)2026年中期业绩：营收10.07亿元，经调整净利润1.28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154969936","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154969936?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:26","pubTimestamp":1787740013,"startTime":"0","endTime":"0","summary":"维亚生物披露截至2026年6月30日止六个月的财务数据，营收约10.07亿元，同比增长21.0%。期内经调整非国际财务报告准则净利润约1.28亿元，同比下降30.1%，对应净利率从上年同期的22.1%降至12.7%。同期毛利约3.42亿元，毛利率为34.0%，对比上年同期的40.8%有所下滑。药物发现服务板块报告期业务收入约4.05亿元，同比减少4.2%，如扣除汇率因素则降幅约1.2%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"维亚生物(01873)2026年中期业绩：营收10.07亿元，经调整净利润1.28亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662790813","title":"维亚生物(01873.HK)发布中期业绩，经调整净利润1.28亿元 同比减少30.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790813","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662790813?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:26","pubTimestamp":1787739967,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1576","01873","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200320","title":"医药外包概念盘初普升 凯莱英（06821）涨6.21% 机构指CXO行业景气上行逻辑不断夯实","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200320","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662200320?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:57","pubTimestamp":1787623040,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初普升，截至发稿，凯莱英 涨6.21%，金斯瑞生物科技涨4.78%，药明生物涨2.22%，维亚生物涨1.67%，泰格医药涨1.05%。消息面上，国金证券表示，CXO行业景气度持续向上，全球生物医药投融资回暖带动创新药研发投入提速，海内外龙头订单与业绩逐步兑现，行业景气上行逻辑不断夯实。头部CXO企业也主动融合AI能力，迭代实验与生产体系。在传统创新药需求叠加AI制药增量的共振之下，行业中长期成长空间进一步打开。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989237","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518931.SGD","LU0051755006.USD","KURE","LU0456827905.SGD","BK0239","BK0132","LU0348825331.USD","LU0856984785.SGD","CXO","HK0000320264.USD","LU0359202008.SGD","WX","01873","02269","LU1720050803.USD","SG9999002562.SGD","LU0516422440.USD","LU0708995583.HKD","LU0516423091.SGD","LU1794554557.SGD","LU0029874061.USD","LU1242518857.USD","LU1880383366.USD","LU0516422366.SGD","LU0979878070.USD","LU0181495838.USD","LU0456846285.SGD","LU0326950275.SGD","LU0359201612.USD","HK0000306685.HKD","LU0039217434.USD","BK1610","06821","HK0000320223.HKD","LU0140636845.USD","LU0307460666.USD","01548","BK1515","03347","002821","09939","BK1191","LU0516422952.EUR","LU0052750758.USD","159938","LU0819121731.USD","BK1589","BK1161","SG9999002463.SGD","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109351794","title":"维亚生物(01873)定于2026年8月26日召开董事会 审议中期业绩及派息计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1109351794","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109351794?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:37","pubTimestamp":1786696620,"startTime":"0","endTime":"0","summary":"维亚生物(01873)8月14日公告称，公司董事会将于2026年8月26日（星期三）召开会议，主要议程包括：一、审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及相关公告；二、研究及考虑建议派发中期股息（如有）。\n\n截至公告日，维亚生物董事会由三名执行董事（主席兼首席执行官毛晨、吴鹰、任德林）、一名非执行董事（吴宇挺）及三名独立非执行董事（傅磊、李向荣、王海光）组成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659299118","title":"创新药概念集体回调 康方生物（09926）跌6.85%、维亚生物（01873）跌6.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659299118","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659299118?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:51","pubTimestamp":1786686711,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念集体回调，康方生物 跌6.85%，维亚生物跌6.33%，思路迪医药股份跌6.15%，恒瑞医药跌5.10%，晶泰控股跌4.88%，凯莱英跌4.67%，亚盛医药跌4.04%，药明康德跌3.94%，百济神州跌3.92%。西南证券表示，CXO+创新药放量领涨，8-9月有望迎来业绩+临床数据共振。从产业链的角度，CXO板块投融资改善明显，26H1中国/全球医疗健康投融资分别676.47亿元/2416.43亿元，ADC、多肽、细胞基因治疗等新药物形式赛道持续火热，头部CXO公司海外订单复苏明显。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988233","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","IE00B5MMRT66.SGD","LU0634319403.HKD","BK1574","LU1251922891.USD","LU1794554557.SGD","LU1770034418.SGD","LU1720050803.USD","LU0828237510.HKD","LU0228659784.USD","LU2242644610.SGD","LU0708995583.HKD","LU0307460666.USD","LU2399975544.HKD","BK1588","BK1576","KURE","01244","BK1617","LU0052750758.USD","LU0348766576.USD","LU2476274720.SGD","06160","LU2778985437.USD","01873","06978","LU0348784397.USD","LU1719994722.HKD","IBBQ","06821","IE00B543WZ88.USD","01276","LU0561508036.HKD","159992","02359","LU0359201612.USD","LU0359202008.SGD","LU1961090484.USD","LU2045819591.USD","06855","02228","LU0348827113.USD","LU0588546209.SGD","MEDX","LU0348783233.USD","LU0327786744.USD","LU2476274308.USD","LU0572944931.SGD","09926","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658609113","title":"医药外包概念股集体扬升 药明生物（02269）涨4.36% 机构指行业景气度上行信号明确","url":"https://stock-news.laohu8.com/highlight/detail?id=2658609113","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658609113?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:58","pubTimestamp":1786327110,"startTime":"0","endTime":"0","summary":"消息面上，国金证券发布研报指，CXO行业已完整经历一轮产业周期，当下行业景气度上行信号明确。目前，随着外部压力缓释、全球投融资回暖，国内BD持续升温，行业已进入内外需共振、新分子赛道放量、订单与业绩逐季改善的新一轮复苏上行周期。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987777","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","LU0181495838.USD","LU2039709279.SGD","LU1242518857.USD","LU0708995583.HKD","LU2242644610.SGD","BK1141","BK1574","HK0000320264.USD","LU0051755006.USD","BK1589","LU1046422090.SGD","LU0456827905.SGD","LU0819121731.USD","BK1191","LU0043850808.USD","LU1720050803.USD","LU0320764599.SGD","02269","LU0823426480.USD","01521","01873","LU0516423174.USD","BK1515","09939","06821","KURE","06127","LU0823426308.USD","LU1242518931.SGD","LU2125910500.SGD","LU0417516738.SGD","LU1880383366.USD","LU0588546209.SGD","LU0979878070.USD","LU0052750758.USD","LU0572944931.SGD","BK1576","LU0348767384.USD","BK1161","BK1521","LU0307460666.USD","LU3063872942.SGD","SG9999002562.SGD","159938","LU0140636845.USD","LU0516422366.SGD","HK0000306701.USD","IE00B0JY6N72.USD","02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102630842","title":"维亚生物更新7月股份变动月报，回购并注销1101.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1102630842","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102630842?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:22","pubTimestamp":1785828142,"startTime":"0","endTime":"0","summary":"维亚生物科技控股集团于2026年8月4日发布截至2026年7月31日的股份变动月报。公告显示，公司报告期内法定股本和注册股本均未发生变动，维持在4,000,000,000股，面值为每股USD 0.000025，总额约USD 100,000。公告同时显示，公司目前已发行股份总数在月内出现变动，期末较月初减少11,011,500股。公司声明已遵守香港联交所《上市规则》及相关法律法规要求，并确认在报告期末持有足够的公众持股量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656863415","title":"药明康德（02359）中期业绩提振医药外包概念股 凯莱英（06821）涨7.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656863415","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656863415?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:36","pubTimestamp":1785807412,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药明康德 中期业绩强劲，推动股价大涨逾14%，同步提振医药外包概念股，凯莱英涨7.98%，康龙化成涨7.58%，泰格医药涨5.62%，金斯瑞生物科技涨6.01%，药明生物涨4.95%，昭衍新药涨4.93%，维亚生物涨1.96%。据药明康德公告，上半年公司实现营业收入288.97亿元，同比增长38.93%；归属于上市公司股东的净利润110.8亿元，同比增长29.43%；扣非净利润105.72亿元，同比增长89.39%。公司计划上半年向全体股东每10股派发现金红利5.10元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987415","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821","BK1583","LU1046422090.SGD","HK0000306685.HKD","LU0611395673.USD","IE00BPRC5H50.USD","LU2488822045.USD","HK0000320223.HKD","SG9999002562.SGD","IE00B5MMRT66.SGD","03759","02269","LU0856984785.SGD","LU1251922891.USD","BK1610","LU0348766576.USD","09939","LU2045819591.USD","KURE","LU0181495838.USD","02359","002821","01873","LU0039217434.USD","01548","603259","LU0456842615.SGD","03347","BK0239","LU2495084118.USD","BK1191","BK1515","LU0979878070.USD","BK1576","HK0000320264.USD","06127","LU1997245094.SGD","LU1303224171.USD","BK1589","LU0359202008.SGD","159938","LU1688375341.USD","LU0516422440.USD","LU0307460666.USD","LU1808992512.USD","LU2242644610.SGD","LU0700851271.USD","LU0320764599.SGD","LU0348767384.USD","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654095486","title":"医药外包概念全线扬升 昭衍新药(06127)涨7.93% 机构指CXO景气进入中报业绩兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654095486","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654095486?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:17","pubTimestamp":1785118673,"startTime":"0","endTime":"0","summary":"消息面上，开源证券新近研究指出，7月以来，康龙化成、昭衍新药、美迪西和药康生物先后发布2026年H1业绩预增公告，从早研到临床前研究，CXO景气周期已逐步进入利润表兑现期。根据医药魔方，2026H1全球创新药一级市场共发生505起融资事件，同比增长6.1%，融资金额达到267.5亿美元，同比增长58.5%。2026H1中国相关交易数量及金额涨势迅猛，总金额达997亿美元。从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986787","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","BK1191","LU0348766576.USD","LU2125910500.SGD","LU1046422090.SGD","LU3063872942.SGD","LU1242518857.USD","LU0516422952.EUR","LU0327786744.USD","06127","LU0140636845.USD","01548","CXO","LU1880383366.USD","HK0000306685.HKD","LU2039709279.SGD","LU2242644610.SGD","WX","LU1242518931.SGD","09939","LU0307460666.USD","BK1589","LU0039217434.USD","BK0216","BK1610","SG9999002562.SGD","LU0348767384.USD","LU0823426480.USD","BK1574","LU0043850808.USD","LU0516422440.USD","LU0856984785.SGD","BK1141","KURE","01873","LU0417516738.SGD","LU0823426308.USD","HK0000320264.USD","LU0348735423.USD","LU0516423174.USD","LU0588546209.SGD","BK1161","159938","06821","BK1583","603127","LU0359201612.USD","03347","03759","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653782367","title":"维亚生物(01873.HK)转仓市值总计1.56亿港元 占比5.92% 从星展银行转出1.2亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653782367","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653782367?lang=zh_cn&edition=full","pubTime":"2026-07-22 08:39","pubTimestamp":1784680751,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01873","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136000641","title":"维亚生物：6月8日至6月26日回购1101.15万股，耗资约1252.66万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136000641","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136000641?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:06","pubTimestamp":1784020007,"startTime":"0","endTime":"0","summary":"2026年7月14日，维亚生物科技控股集团（股票代码：01873）公告，基于翌日披露报表显示，公司于2026年6月8日至6月26日期间回购合共1101.15万股，占当时已发行股本的约0.5232%，平均每股回购价格为1.137593港元，合计耗资约1252.66万港元。该批已回购股份于2026年7月14日注销。\n本次回购完成后，公司已发行股本减少至20.94亿股，库藏股数为0。公司表示，其已遵守香港联合交易所有限公司证券上市规则及其他适用法律法规的相关要求。该公告由执行董事毛晨签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"维亚生物：6月8日至6月26日回购1101.15万股，耗资约1252.66万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651176982","title":"维亚生物(01873)7月14日注销1101.15万股已购回股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2651176982","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651176982?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:06","pubTimestamp":1784019967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维亚生物(01873)发布公告，于2026年7月14日该公司注销1101.15万股已购回股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","01873","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192496145","title":"维亚生物更新6月股份变动月报表，股本出现减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1192496145","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192496145?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:54","pubTimestamp":1783328056,"startTime":"0","endTime":"0","summary":"维亚生物科技控股集团于2026年7月6日发布截至2026年6月30日的股份变动月报，公告期间公司的法定股本保持在4,000,000,000股普通股，面值每股USD 0.000025，总面值100,000美元，未发生变动。截至2026年6月30日，维亚生物已发行股份总数为2,104,564,853股，较上月底的2,129,882,353股减少25,317,500股。本月内，维亚生物进行了多笔股份购回操作，其中25,317,500股已回购并注销，导致本月末已发行股份数量相应减少；另有合计11,011,500股回购股份尚未注销。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136907019","title":"维亚生物再度回购152.60万股股份，耗资约169.44万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136907019","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136907019?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:33","pubTimestamp":1782473623,"startTime":"0","endTime":"0","summary":"维亚生物科技控股集团（股票代码：01873）2026年6月26日公告，披露当日于香港联交所场内进行股份回购，涉及1,526,000股，约占公司已发行股本0.0725%。每股最高回购价为1.12港元，最低回购价为1.09港元，合计耗资约169.44万港元。\n根据公告，公司截至2026年6月26日的已发行股本仍为2,104,564,853股，暂无库藏股。本次回购已获董事会批准，并遵守相关上市规则及法律规定。此外，公司于2026年6月26日获得回购授权，总数为209,507,935股，此次回购占当日授权总数的0.0728%。\n公告由执行董事毛晨签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维亚生物再度回购152.60万股股份，耗资约169.44万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646354880","title":"维亚生物(01873)6月26日斥资约169.44万港元回购152.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646354880","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646354880?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:24","pubTimestamp":1782473090,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维亚生物(01873)发布公告，于2026年6月26日该公司斥资约169.44万港元回购152.6万股，回购价格为每股1.09至1.12港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK1141","01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646870490","title":"维亚生物(01873)授出622.4万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2646870490","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646870490?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:12","pubTimestamp":1782389578,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维亚生物(01873)发布公告，公司于2026年6月25日根据公司于2020年6月5日采纳的受限制股份单位计划，向若干合资格参与者授出受限制股份单位，据此，承授人根据授出条款将有权获得合共最多622.4万股公司普通股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","01873","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194486804","title":"维亚生物科技控股集团6月25日回购350万股，涉资约372.19万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194486804","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194486804?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:26","pubTimestamp":1782383170,"startTime":"0","endTime":"0","summary":"维亚生物科技控股集团于2026年6月25日发布公告，披露当日于香港联交所场内回购3,500,000股普通股，约占回购日前该公司已发行股本的0.1663%。最高回购价格为每股1.10港元，最低回购价格为每股1.04港元，合共付出的代价约为3,721,870港元。根据公告，完成上述回购后，公司已发行股本仍为2,104,564,853股，因该批回购股份尚未注销。公司确认已遵守香港联交所证券上市规则及相关适用法律法规。上述信息由维亚生物科技控股集团执行董事毛晨签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维亚生物科技控股集团6月25日回购350万股，涉资约372.19万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivabiotech.com","stockEarnings":[{"period":"1week","weight":-0.0328},{"period":"1month","weight":-0.0799},{"period":"3month","weight":0.1522},{"period":"6month","weight":-0.4502},{"period":"1year","weight":-0.5268},{"period":"ytd","weight":-0.2639}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0188},{"period":"1year","weight":-0.0002},{"period":"ytd","weight":-0.0085}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"维亚生物科技控股集团是一家投资控股公司。该公司有两个分部。药物发现服务分部提供就临床前创新药物开发向生物科技及制药客户提供基于结构的药物发现服务。同研发生产组织务（CDMO）及商业化服务分部从事小分子原料药及中间体的合同研发生产服务以及买卖原料药、中间体及制剂。该公司主要在美国、中国、欧洲和其他地区开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.080145},{"month":2,"riseRate":0.285714,"avgChangeRate":0.018359},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.001599},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.030961},{"month":5,"riseRate":0.571429,"avgChangeRate":0.174922},{"month":6,"riseRate":0.25,"avgChangeRate":-0.042908},{"month":7,"riseRate":0.75,"avgChangeRate":0.027666},{"month":8,"riseRate":0.5,"avgChangeRate":0.043169},{"month":9,"riseRate":0.25,"avgChangeRate":0.014936},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.044725},{"month":11,"riseRate":0.142857,"avgChangeRate":-0.040545},{"month":12,"riseRate":0.571429,"avgChangeRate":0.026236}],"exchange":"SEHK","name":"维亚生物","nameEN":"VIVA BIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维亚生物(01873)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维亚生物(01873)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维亚生物,01873,维亚生物股票,维亚生物股票老虎,维亚生物股票老虎国际,维亚生物行情,维亚生物股票行情,维亚生物股价,维亚生物股市,维亚生物股票价格,维亚生物股票交易,维亚生物股票购买,维亚生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维亚生物(01873)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维亚生物(01873)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}